DE122006000007I1 - Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. - Google Patents

Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.

Info

Publication number
DE122006000007I1
DE122006000007I1 DE19883853636 DE3853636C DE122006000007I1 DE 122006000007 I1 DE122006000007 I1 DE 122006000007I1 DE 19883853636 DE19883853636 DE 19883853636 DE 3853636 C DE3853636 C DE 3853636C DE 122006000007 I1 DE122006000007 I1 DE 122006000007I1
Authority
DE
Germany
Prior art keywords
ige
lymphocytes
bearing
exclusively
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19883853636
Other languages
English (en)
Other versions
DE3853636D1 (de
DE3853636T3 (de
DE3853636T2 (de
Inventor
Tse-Wen Chang
Bill Nai-Chau Sun
Cecily Rou-Yun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27538114&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122006000007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/226,421 external-priority patent/US5422258A/en
Priority claimed from US07/272,243 external-priority patent/US5091313A/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of DE122006000007I1 publication Critical patent/DE122006000007I1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE19883853636 1987-12-31 1988-12-29 Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden. Pending DE122006000007I1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14003687A 1987-12-31 1987-12-31
US07/226,421 US5422258A (en) 1987-12-31 1988-07-29 Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US22917888A 1988-08-05 1988-08-05
US07/272,243 US5091313A (en) 1988-08-05 1988-11-16 Antigenic epitopes of IgE present on B cell but not basophil surface
US29106888A 1988-12-28 1988-12-28
PCT/US1988/004706 WO1989006138A1 (en) 1987-12-31 1988-12-29 UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES

Publications (1)

Publication Number Publication Date
DE122006000007I1 true DE122006000007I1 (de) 2006-04-27

Family

ID=27538114

Family Applications (3)

Application Number Title Priority Date Filing Date
DE3853636T Expired - Lifetime DE3853636T3 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE19883853636 Pending DE122006000007I1 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
DE122006000007C Active DE122006000007I2 (de) 1987-12-31 1988-12-29 -tragenden b-lymphocyten befinden.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3853636T Expired - Lifetime DE3853636T3 (de) 1987-12-31 1988-12-29 Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122006000007C Active DE122006000007I2 (de) 1987-12-31 1988-12-29 -tragenden b-lymphocyten befinden.

Country Status (10)

Country Link
EP (2) EP0617127A1 (de)
JP (1) JP2724625B2 (de)
AT (1) ATE121299T1 (de)
AU (1) AU618317B2 (de)
CA (1) CA1340233C (de)
DE (3) DE3853636T3 (de)
HK (1) HK31096A (de)
LU (1) LU91218I2 (de)
NL (1) NL300222I2 (de)
WO (1) WO1989006138A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5362643A (en) * 1989-06-21 1994-11-08 Tanox Biosystems Antibodies to epitopes present on membrane-bound but not secreted IGA
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
EP0327283B1 (de) * 1988-02-02 1993-08-18 Schering Biotech Corporation Methode zur Verminderung der Immunglobulin-E-Reaktion
ATE148348T1 (de) * 1989-09-15 1997-02-15 Tanox Biosystems Inc Behandlung von einer autoimmun-krankheit
SG70982A1 (en) * 1990-01-23 2000-03-21 Tanox Biosystems Inc Extracellular segments of human and immunoglobulin anchoring peptides and antibodies specific therefor
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US5994514A (en) * 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
EP0602126B1 (de) * 1991-08-14 2003-03-05 Genentech, Inc. Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
GB9220228D0 (en) * 1992-09-24 1992-11-04 Ciba Geigy Ag Reshaped monoclonal antibodies against an immunologlobulin isotype
DK0589840T3 (da) * 1992-09-24 2004-07-26 Novartis Ag Omdannede monoklonale antistoffer mod en immunoglobulinisotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
WO1994020533A1 (en) * 1993-03-11 1994-09-15 Tanox Biosystems, Inc. PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE
EP0619323A1 (de) * 1993-04-09 1994-10-12 Schering-Plough Menschliche monoklonale Antikörper und Verfahren und Material zu deren Herstellung
DK0739214T3 (da) * 1994-01-18 1998-10-07 Genentech Inc Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP2788979B2 (ja) * 1995-08-28 1998-08-20 タノックス バイオシステムズ インコーポレイテッド 新規抗体及びその用途
US7026446B1 (en) 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1592776A4 (de) 2003-02-01 2008-06-04 Tanox Inc Hochaffine anti-mensch-ige-antikörper
JP5389442B2 (ja) 2005-09-29 2014-01-15 メディミューン，エルエルシー 膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
KR101555068B1 (ko) 2007-03-22 2015-10-06 제넨테크, 인크. 막 결합형 ｉｇｅ에 결합하는 세포자멸성 항-ｉｇｅ 항체
EP1972640A1 (de) * 2007-03-23 2008-09-24 Biomay AG Apoptoseerzeugende Antikörper
CN102482351B (zh) 2009-02-25 2015-03-18 中央研究院 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
KR20200110302A (ko) 2017-10-31 2020-09-23 원니스 바이오테크 컴퍼니 리미티드 IgE-매개 알레르기성 질환들의 치료

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
CA1338777C (en) * 1986-11-04 1996-12-10 Dominic Man-Kit Lam Methods and compositions for preventing secondary cataracts
GB8800078D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies

Also Published As

Publication number Publication date
AU3031089A (en) 1989-08-01
EP0407392A1 (de) 1991-01-16
WO1989006138A1 (en) 1989-07-13
ATE121299T1 (de) 1995-05-15
JP2724625B2 (ja) 1998-03-09
EP0617127A1 (de) 1994-09-28
EP0407392B1 (de) 1995-04-19
DE122006000007I2 (de) 2008-03-27
EP0407392B2 (de) 1998-10-28
DE3853636D1 (de) 1995-05-24
NL300222I1 (nl) 2006-04-03
NL300222I2 (nl) 2006-10-02
DE3853636T3 (de) 1999-04-08
JPH03501927A (ja) 1991-05-09
CA1340233C (en) 1998-12-15
AU618317B2 (en) 1991-12-19
HK31096A (en) 1996-03-01
LU91218I2 (fr) 2006-04-03
DE3853636T2 (de) 1995-08-24

Similar Documents

Publication Publication Date Title
DE122006000007I1 (de) Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
ATE47155T1 (de) Monoklonaler antikoerper.
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
KR900702007A (ko) T세포 항원 수용체의 지어부위와 반응하는 단클론항체
IT8019656A0 (it) Polimeri idrocarburici ionici con migliorata adesione al nylon.
DE69032979D1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
ATE177475T1 (de) Monoklonale antikörper gegen c-kit
ES2176347T3 (es) Modulacion de la respuesta inmune.
DE3885355D1 (de) Monoklonale Antikörper.
DE68922482D1 (de) Auflegevorrichtung für gummierte Bahnen.
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DK191989A (da) Tumor-associeret glycoproteinantigen, antistoffer mod antigenet samt hybridoma-cellelinie, der producerer antistofferne
IT8121211A0 (it) Procedimento di conversione di olii pesanti di idrocarburi contenenti degli asfalteni, in frazioni piu'leggere.
IT8026986A0 (it) Antigene di prostata umana purificato e procedimento per preparare anticorpi correlati a tale antigene.
IT8021411A0 (it) Polipeptide sintetico attivo come antigene, e procedimento per la sua preparazione.
NO870457L (no) Beskyttende monoklonale menneskeantistoffer mot pseudomonas aeruginosa eksotoksin.
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
IT8420971A0 (it) Procedimento per la conversione di olifine in idrocarburi di peso molecolare piu' elevato con catalizzatore di silicalite.
ATE73463T1 (de) Monoklonale antikoerper.
IT7920799A0 (it) Processo per la copolimerizzazione dell'etilene con idrocarburi pluriinsaturi.
SU887878A1 (ru) Демпфирующее устройство
IT8121653A0 (it) Caratteristiche di rigenerazione. catalizzatore per la conversione di idrocarburi dotato di migliori
NO892941D0 (no) Monoklonalt antistoff mot den rgd-rettede adhesjonsreseptor paa endotelceller.
SU568934A1 (ru) Устройство прив зки шкалы времени
FI894652A (fi) Hybridom c10g7, som producerar monoklonala antikroppar mot en antigengrupp i bukspottskoertelns b-celler, vilken har en molekylmassa av 64-69 kilodalton.